Therapeutic Drug Monitoring (TDM) of Antifungal Agents: Guidelines from the British Society for Medical Mycology

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2014 Jan 1

PMID 24379304

Citations 228

Authors

H Ruth Ashbee

Rosemary A Barnes

Elizabeth M Johnson

Malcolm D Richardson

Rebecca Gorton

William W Hope

Affiliations

Soon will be listed here.

Abstract

The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.

Citing Articles

Voriconazole in the treatment of pediatric patients with hematologic malignancies and invasive fungal infections: a real-world study.

Wu N, Cai L, Zhang Q, Fan Y, Lin Z Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 40057934 DOI: 10.1007/s10096-025-05067-y.

Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease.

Cortes J, Rodriguez-Lugo D, Valderrama-Rios M, Rabagliati R, Capone D, Alvarez-Moreno C Braz J Infect Dis. 2025; 29(2):104517.

PMID: 39999620 PMC: 11903820. DOI: 10.1016/j.bjid.2025.104517.

Therapeutic drug monitoring of posaconazole oral suspension in paediatric hematology patients under 13 years of age.

Du X, Yan Y, Li F, Zhou M, Yang M, Hu S Transl Pediatr. 2025; 14(1):4-13.

PMID: 39944866 PMC: 11811588. DOI: 10.21037/tp-24-400.

Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders-A Single-Centre Study.

Liszka K, Marschollek P, Przystupski D, Fraczkiewicz J, Mielcarek-Siedziuk M, Olejnik I J Fungi (Basel). 2025; 11(1).

PMID: 39852457 PMC: 11766596. DOI: 10.3390/jof11010038.

The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug....

Adamiszak A, Czyrski A, Sznek B, Grzeskowiak E, Bienert A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770521 PMC: 11679493. DOI: 10.3390/ph17121679.

References

Muller C, Arndt M, Queckenberg C, Cornely O, Theisohn M . HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses. 2006; 49 Suppl 1:17-22. DOI: 10.1111/j.1439-0507.2006.01297.x. View

Odds F, Van Gerven F, Espinel-Ingroff A, Bartlett M, Ghannoum M, Lancaster M . Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998; 42(2):282-8. PMC: 105401. DOI: 10.1128/AAC.42.2.282. View

Troke P, Hockey H, Hope W . Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011; 55(10):4782-8. PMC: 3186950. DOI: 10.1128/AAC.01083-10. View

Hope W . Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother. 2011; 56(1):526-31. PMC: 3256045. DOI: 10.1128/AAC.00702-11. View

Imhof A, Schaer D, Schanz U, Schwarz U . Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006; 136(45-46):739-42. DOI: 10.4414/smw.2006.11547. View

Kim K, Lee S, Lee S, Yun N, Kim N, Yu K . Voriconazole-associated severe hyponatremia. Med Mycol. 2011; 50(1):103-5. DOI: 10.3109/13693786.2011.587210. View

Bruggemann R, Alffenaar J, Blijlevens N, Billaud E, Kosterink J, Verweij P . Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009; 48(10):1441-58. DOI: 10.1086/598327. View

Dolton M, Ray J, Chen S, Ng K, Pont L, McLachlan A . Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012; 56(11):5503-10. PMC: 3486529. DOI: 10.1128/AAC.00802-12. View

Bellmann R . Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol. 2008; 2(1):37-58. DOI: 10.2174/157488407779422311. View

10.

Campoli P, Al Abdallah Q, Robitaille R, Solis N, Fielhaber J, Kristof A . Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011; 55(12):5732-9. PMC: 3232766. DOI: 10.1128/AAC.00637-11. View

11.

Howard S, Felton T, Gomez-Lopez A, Hope W . Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit. 2012; 34(1):72-6. DOI: 10.1097/FTD.0b013e31823cdeac. View

12.

Serena C, Gilgado F, Marine M, Pastor F, Guarro J . Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother. 2006; 50(6):2240-3. PMC: 1479129. DOI: 10.1128/AAC.00045-06. View

13.

Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C . Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999; 42(7-8):443-51. DOI: 10.1046/j.1439-0507.1999.00505.x. View

14.

Denning D, TUCKER R, Hanson L, Stevens D . Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989; 86(6 Pt 2):791-800. DOI: 10.1016/0002-9343(89)90475-0. View

15.

Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V . Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852(1-2):223-8. DOI: 10.1016/j.jchromb.2007.01.021. View

16.

Howard S, Cerar D, Anderson M, Albarrag A, Fisher M, Pasqualotto A . Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009; 15(7):1068-76. PMC: 2744247. DOI: 10.3201/eid1507.090043. View

17.

Shields R, Clancy C, Vadnerkar A, Kwak E, Silveira F, Abdel Massih R . Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2010; 55(3):1308-11. PMC: 3067082. DOI: 10.1128/AAC.01325-10. View

18.

Ducharme M, Slaughter R, Warbasse L, Chandrasekar P, Van De Velde V, Mannens G . Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther. 1995; 58(6):617-24. DOI: 10.1016/0009-9236(95)90017-9. View

19.

Odabasi Z, Paetznick V, Rodriguez J, Chen E, Rex J, Leitz G . Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Mycoses. 2009; 53(5):438-42. DOI: 10.1111/j.1439-0507.2009.01733.x. View

20.

Tonini J, Thiebaut A, Jourdil J, Berruyer A, Bulabois C, Cahn J . Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother. 2012; 56(10):5247-52. PMC: 3457412. DOI: 10.1128/AAC.00815-12. View